Literature DB >> 25359405

[Antiplatelet therapy after acute coronary syndrome. Therapeutic strategies and treatment duration].

C B Olivier1, P Diehl, C Bode, M Moser.   

Abstract

Besides percutaneous coronary interventions, antiplatelet drugs are of overwhelming importance for patients with acute coronary syndrome (ACS). For ACS patients, the guidelines recommend treatment with acetylsalicylic acid and a P2Y12 receptor antagonist. The third generation P2Y12 receptor antagonists prasugrel and ticagrelor provide stronger platelet inhibition than clopidogrel and improve the clinical outcome in patients with ACS; however, it is still under discussion which P2Y12 antagonist fits best to which subgroup of ACS patients. This article summarizes current guidelines and antiplatelet treatment strategies for patients with non-ST-segment elevation (NSTE) ACS or ST-segment elevation myocardial infarction (STEMI). The information is mainly based on the recently published guidelines of the European Society of Cardiology on myocardial revascularization.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25359405     DOI： 10.1007/s00059-014-4162-6

Source DB:  PubMed          Journal:  Herz        ISSN： 0340-9937            Impact factor:   1.443


  40 in total

1.  P2Y12 inhibitors in acute coronary syndromes: how do we choose the best drug for our patients?

Authors:  Steen D Kristensen; Erik L Grove; Anne-Mette Hvas
Journal:  Thromb Haemost       Date:  2012-06-28       Impact factor: 5.249

2.  Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease.

Authors:  Tomas Jernberg; Christopher D Payne; Kenneth J Winters; Christelle Darstein; John T Brandt; Joseph A Jakubowski; Hideo Naganuma; Agneta Siegbahn; Lars Wallentin
Journal:  Eur Heart J       Date:  2006-04-18       Impact factor: 29.983

3.  A high ratio of ADP-TRAP induced platelet aggregation is associated more strongly with increased mortality after coronary stent implantation than high conventional ADP induced aggregation alone.

Authors:  Christoph B Olivier; Katharina Schnabel; Christoph Brandt; Patrick Weik; Manfred Olschewski; Qian Zhou; Christoph Bode; Philipp Diehl; Martin Moser
Journal:  Clin Res Cardiol       Date:  2014-07-16       Impact factor: 5.460

4.  2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI).

Authors:  Philippe Kolh; Stephan Windecker; Fernando Alfonso; Jean-Philippe Collet; Jochen Cremer; Volkmar Falk; Gerasimos Filippatos; Christian Hamm; Stuart J Head; Peter Jüni; A Pieter Kappetein; Adnan Kastrati; Juhani Knuuti; Ulf Landmesser; Günther Laufer; Franz-Josef Neumann; Dimitrios J Richter; Patrick Schauerte; Miguel Sousa Uva; Giulio G Stefanini; David Paul Taggart; Lucia Torracca; Marco Valgimigli; William Wijns; Adam Witkowski; Jose Luis Zamorano; Stephan Achenbach; Helmut Baumgartner; Jeroen J Bax; Héctor Bueno; Veronica Dean; Christi Deaton; Çetin Erol; Robert Fagard; Roberto Ferrari; David Hasdai; Arno W Hoes; Paulus Kirchhof; Juhani Knuuti; Philippe Kolh; Patrizio Lancellotti; Ales Linhart; Petros Nihoyannopoulos; Massimo F Piepoli; Piotr Ponikowski; Per Anton Sirnes; Juan Luis Tamargo; Michal Tendera; Adam Torbicki; William Wijns; Stephan Windecker; Miguel Sousa Uva; Stephan Achenbach; John Pepper; Anelechi Anyanwu; Lina Badimon; Johann Bauersachs; Andreas Baumbach; Farzin Beygui; Nikolaos Bonaros; Marco De Carlo; Christi Deaton; Dobromir Dobrev; Joel Dunning; Eric Eeckhout; Stephan Gielen; David Hasdai; Paulus Kirchhof; Heyman Luckraz; Heiko Mahrholdt; Gilles Montalescot; Domenico Paparella; Ardawan J Rastan; Marcelo Sanmartin; Paul Sergeant; Sigmund Silber; Juan Tamargo; Jurrien ten Berg; Holger Thiele; Robert-Jan van Geuns; Hans-Otto Wagner; Sven Wassmann; Olaf Wendler; Jose Luis Zamorano
Journal:  Eur J Cardiothorac Surg       Date:  2014-08-29       Impact factor: 4.191

5.  Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study.

Authors:  Dominick J Angiolillo; Jorge F Saucedo; Roger Deraad; Andrew L Frelinger; Paul A Gurbel; Timothy M Costigan; Joseph A Jakubowski; Clement K Ojeh; Mark B Effron
Journal:  J Am Coll Cardiol       Date:  2010-09-21       Impact factor: 24.094

6.  Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.

Authors:  Philippe Gabriel Steg; Stefan James; Robert A Harrington; Diego Ardissino; Richard C Becker; Christopher P Cannon; Håkan Emanuelsson; Ariel Finkelstein; Steen Husted; Hugo Katus; Jan Kilhamn; Sylvia Olofsson; Robert F Storey; W Douglas Weaver; Lars Wallentin
Journal:  Circulation       Date:  2010-11-08       Impact factor: 29.690

7.  Clopidogrel non-responsiveness and risk of cardiovascular morbidity. An updated meta-analysis.

Authors:  Francesco Sofi; Rossella Marcucci; Anna Maria Gori; Betti Giusti; Rosanna Abbate; Gian Franco Gensini
Journal:  Thromb Haemost       Date:  2010-02-02       Impact factor: 5.249

8.  Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial.

Authors:  Adnan Kastrati; Julinda Mehilli; Franz-Josef Neumann; Franz Dotzer; Jurriën ten Berg; Hildegard Bollwein; Isolde Graf; Maryam Ibrahim; Jürgen Pache; Melchior Seyfarth; Helmut Schühlen; Josef Dirschinger; Peter B Berger; Albert Schömig
Journal:  JAMA       Date:  2006-03-13       Impact factor: 56.272

9.  Benefits from small molecule administration as compared with abciximab among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-analysis.

Authors:  Giuseppe De Luca; Grazia Ucci; Ettore Cassetti; Paolo Marino
Journal:  J Am Coll Cardiol       Date:  2009-05-05       Impact factor: 24.094

10.  Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38.

Authors:  Stephen D Wiviott; Eugene Braunwald; Dominick J Angiolillo; Simha Meisel; Anthony J Dalby; Freek W A Verheugt; Shaun G Goodman; Ramon Corbalan; Drew A Purdy; Sabina A Murphy; Carolyn H McCabe; Elliott M Antman
Journal:  Circulation       Date:  2008-08-31       Impact factor: 29.690
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.